Does IPILIMUMAB Cause Immune-mediated hepatitis? 443 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 443 reports of Immune-mediated hepatitis have been filed in association with IPILIMUMAB (YERVOY). This represents 1.2% of all adverse event reports for IPILIMUMAB.
443
Reports of Immune-mediated hepatitis with IPILIMUMAB
1.2%
of all IPILIMUMAB reports
58
Deaths
258
Hospitalizations
How Dangerous Is Immune-mediated hepatitis From IPILIMUMAB?
Of the 443 reports, 58 (13.1%) resulted in death, 258 (58.2%) required hospitalization, and 65 (14.7%) were considered life-threatening.
Is Immune-mediated hepatitis Listed in the Official Label?
Yes, Immune-mediated hepatitis is listed as a known adverse reaction in the official FDA drug label for IPILIMUMAB.
What Other Side Effects Does IPILIMUMAB Cause?
Death (3,710)
Malignant neoplasm progression (3,296)
Diarrhoea (2,557)
Off label use (2,097)
Colitis (1,988)
Pyrexia (1,796)
Rash (1,556)
Fatigue (1,447)
Intentional product use issue (1,329)
Nausea (1,169)
What Other Drugs Cause Immune-mediated hepatitis?
NIVOLUMAB (640)
PEMBROLIZUMAB (549)
CARBOPLATIN (213)
PACLITAXEL (167)
ATEZOLIZUMAB (142)
BEVACIZUMAB (108)
DURVALUMAB (90)
LENVATINIB (86)
PEMETREXED (86)
TREMELIMUMAB (51)
Which IPILIMUMAB Alternatives Have Lower Immune-mediated hepatitis Risk?
IPILIMUMAB vs IPRAGLIFLOZIN L-PROLINE
IPILIMUMAB vs IPRATROPIUM
IPILIMUMAB vs IPRATROPIUM\IPRATROPIUM ANHYDROUS
IPILIMUMAB vs IPTACOPAN
IPILIMUMAB vs IRBESARTAN